University of Sheffield wins global prize for ALS project
The University of Sheffield has been named as one of the winners of the Longitude Prize on ALS for a project using AI to combat motor neurone disease (MND).
The global prize recognised the Sheffield-led ‘Decode ALS’ consortium as one of the world’s most promising multidisciplinary teams of innovators, using AI to find a new drug target for amyotrophic lateral sclerosis (ALS).
The Decode ALS team, led by Professor Johnathan Cooper-Knock and Professor Richard Mead from the Sheffield Institute for Translational Neuroscience (SITraN) in collaboration with researchers from Yale University, Weizmann Institute of Science and Columbia University, has been awarded a £100,000 ($135,000) Discovery Award.
The funding is set to advance a pioneering end-to-end AI pipeline to bridge the gap between genetic discovery and life-saving treatments.
“As a neurologist, I am consistently inspired by the positivity of my patients,” Cooper-Knock said.
“I often see people who give up their time for research they know will not bear fruit in time to help them personally — they are selflessly investing in the search for a cure. We hope our work can finally honour that investment.
“Our unique team combines world-leaders in the application of AI and machine learning with experts in ALS biology to drive therapeutic discovery to completion.”
Decode ALS ‘building the tools’ to stop ALS
The work led by the Sheffield team combines AI across genetics, genomics, disease biology, and drug discovery into what the university calls “a single, seamless system”.
By training AI models on whole-genome sequencing from patients and molecular readouts of the disease, the team can predict how candidate drugs will interact with specific protein structures.
This approach could allow researchers to better understand the causes of ALS and identify potential treatments to halt the progression of the disease.
“At SITraN, we aren’t just looking to understand ALS; we are building the tools to stop it,” Mead added.
“By integrating AI directly into our drug discovery pipeline, we can now decode patient data at a scale and speed that was previously unimaginable. This award validates our approach of turning big data into tangible new medicines, ensuring Sheffield remains at the forefront of the global effort to end this disease.”
The Longitude Prize on ALS is a £7.5 million ($10.1 million) global challenge prize that aims to incentivise and reward cutting edge AI-based approaches to transform drug discovery to treat ALS.
Following a global call to action in June 2025, almost 100 teams representing the world’s leading universities, technology giants, advanced medical research organisations and AI pioneers entered the prize.
